Insulet's Q2 2024 Earnings: What to Expect
Insulet Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $234
Express News | Canaccord Genuity Maintains Buy on Insulet, Maintains $234 Price Target
Insulet Analyst Ratings
Insulet's Growth Prospects Bolstered by AID Technology and Strategic Market Expansion
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
CereVasc Announces Appointments of New Directors
Should You Think About Buying Insulet Corporation (NASDAQ:PODD) Now?
Should You Be Impressed By Insulet Corporation's (NASDAQ:PODD) ROE?
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
Glaukos Cut as Citi Reviews U.S. MedTechs
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
(PODD) - Analyzing Insulet's Short Interest
Why Insulet Corporation (NASDAQ:PODD) Looks Like A Quality Company
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240
Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com